云核医药

Yunhe Pharma (Yunhe Pharmaceuticals) is a wholly-owned subsidiary of Yunnan Baiyao Group, established in July 2023 as the group's core vehicle for radiopharmaceutical research and development. Based in Tianjin, China, the company operates a 6,000-square-meter state-of-the-art nuclear medicine R&D center equipped with advanced imaging, radiochemistry laboratories, and GMP-compliant pilot production lines. Yunhe Pharma focuses on developing high-barrier, high-potential precision diagnostic and therapeutic solutions, particularly targeting prostate cancer through a theranostic approach. Its lead pipeline programs include INR101, a fluorine-18 labeled diagnostic radiopharmaceutical in Phase 3 clinical trials, and INR102, a lutetium-177 labeled therapeutic radiopharmaceutical in Phase 2 clinical trials, both targeting prostate-specific membrane antigen (PSMA).